Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frishman

Showing results (31-40 of 1,857) with videos related to

Pageof 186
Sort By:
American Heart Journal|April 1, 1980
Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 12. Beta-adrenoceptor blockade in myocardial infarction: the continuing controversyW H Frishman
Hospital Practice (Office Ed.)|September 1, 1982
Beta-adrenergic blockade in clinical practiceW H Frishman
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|October 23, 2009
Calcium channel blockers: differences between subclassesWilliam H Frishman
Southern Medical Journal|October 1, 1993
Treatment of myocardial ischemia and myocardial infarction in the elderlyW H Frishman
Heart Disease (Hagerstown, Md.)|April 27, 2002
Cardiopulmonary resuscitation 2000W H Frishman,
Heart Disease (Hagerstown, Md.)|April 27, 2002
Management of unstable angina in 2001W H Frishman
Heart Disease (Hagerstown, Md.)|April 27, 2002
The kidney in the pathophysiology and treatment of cardiovascular diseaseW H Frishman
The American Journal of Medicine|December 16, 2014
Pharmacists in primary careWilliam H Frishman
American Heart Journal|May 1, 1987
Clinical differences between beta-adrenergic blocking agents: implications for therapeutic substitutionW H Frishman
American Heart Journal|November 1, 1988
Circulatory and metabolic aspects of beta-adrenoceptor blockadeW H Frishman
Pageof 186

Showing results (31-40 of 1,857) with videos related to

Sort By:
Pageof 186
American Heart Journal|April 1, 1980
Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 12. Beta-adrenoceptor blockade in myocardial infarction: the continuing controversyW H Frishman
Hospital Practice (Office Ed.)|September 1, 1982
Beta-adrenergic blockade in clinical practiceW H Frishman
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|October 23, 2009
Calcium channel blockers: differences between subclassesWilliam H Frishman
Southern Medical Journal|October 1, 1993
Treatment of myocardial ischemia and myocardial infarction in the elderlyW H Frishman
Heart Disease (Hagerstown, Md.)|April 27, 2002
Cardiopulmonary resuscitation 2000W H Frishman,
Heart Disease (Hagerstown, Md.)|April 27, 2002
Management of unstable angina in 2001W H Frishman
Heart Disease (Hagerstown, Md.)|April 27, 2002
The kidney in the pathophysiology and treatment of cardiovascular diseaseW H Frishman
The American Journal of Medicine|December 16, 2014
Pharmacists in primary careWilliam H Frishman
American Heart Journal|May 1, 1987
Clinical differences between beta-adrenergic blocking agents: implications for therapeutic substitutionW H Frishman
American Heart Journal|November 1, 1988
Circulatory and metabolic aspects of beta-adrenoceptor blockadeW H Frishman
Pageof 186